Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TME Pharma NVXPAR:ALTME -1.29% 5-Year Yield-on-Cost % is 0.00 as of Aug. 05, 2026. The stock has 4 warning signs investors should review. Among 150 Biotechnology companies, TME Pharma NV ranks worse than 666666% on this metric.
TME Pharma NV's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for TME Pharma NV's 5-Year Yield-on-Cost % or its related term are showing as below:
XPAR:ALTME's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.69 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
TME Pharma NV 5-Year Yield-on-Cost % Related Terms
XPAR:ALTME vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, TME Pharma NV's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TME Pharma NV 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TME Pharma NV's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where TME Pharma NV's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of TME Pharma NV is calculated as
TME Pharma NV (XPAR:ALTME) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TME Pharma NV and its competitors. According to the industry distribution chart, TME Pharma NV ranks #999999 out of 150 companies in the Biotechnology industry.
Is TME Pharma NV's 5-Year Yield-on-Cost % too high?
TME Pharma NV's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, TME Pharma NV ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does TME Pharma NV's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TME Pharma NV ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places TME Pharma NV in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.69, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TME Pharma NV and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TME Pharma NV's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALTME has been successfully added to your 
